Online inquiry

IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5242MR)

This product GTTS-WQ5242MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets Factor IX substitute gene. The antibody can be applied in Hemophilia B research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000133.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2158
UniProt ID P00740
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5242MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7164MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ4422MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-663513
GTTS-WQ13175MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-04518600
GTTS-WQ11399MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI-575
GTTS-WQ9263MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-130
GTTS-WQ8184MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HL161
GTTS-WQ9377MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ622MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 7F3com-2H2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW